Login to Your Account

Lawmakers want to know who said what about Epipen rebate

By Mari Serebrov
Regulatory Editor

Wednesday, October 5, 2016

The scrutiny continues of the Medicaid rebate for Mylan NV's Epipen, as the Senate Judiciary Committee seeks more than hearsay on communications between the company and CMS on whether Epipen qualifies for the noninnovator, or generic, rebate.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription